MetaCap

Basel Medical Group (BMGL) vs GeneDx (WGS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

GeneDx is the larger company by market cap ($2.02 billion vs $5.7 million), about 354.6 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

BMGL versus WGS key metrics
MetricBMGLWGS
Share price$3.60$67.73
Market cap$5.70M$2.02B
1-day change+9.76%-1.17%
YTD return—-47.31%
1-year return—-43.25%
5-year return—-73.34%
Forward P/E—56.51
EPS (TTM)$-4.98$-3.63
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$21.72$170.87
52-week low$2.56$32.21
Distance from 52-week high-83.43%-60.36%
Analyst consensus—strong_buy
Avg. price target upside—+38.05%
Average volume529.72K728.47K
Shares outstanding1.58M29.82M
Employees—1,300
SectorHealth CareHealth Care
IndustryMedical/Nursing ServicesMedical/Nursing Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GeneDx is about 354.6 times larger than Basel Medical Group by market value ($2.02B vs $5.70M).

About GeneDx

WGS stock →

GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.

Health Care · Medical/Nursing Services · 1,300 employees

BMGL vs WGS FAQ

Which is bigger, Basel Medical Group or GeneDx?

GeneDx (WGS) is larger, with a market capitalization of $2.02B compared with $5.70M for Basel Medical Group (BMGL).

Are Basel Medical Group and GeneDx in the same industry?

Yes. Both are classified in the Medical/Nursing Services industry within the Health Care sector.

More comparisons